Breast cancer includes a biologically diverse group of tumors that exhibit different metastatic potential and sites and carry different prognoses. The association of breast cancer biologic subtype with locoregional recurrence is underreported. In a retrospective single-institution study by Cheun and colleagues¹ of 16 462 patients treated from 2000 to 2018, there were significant differences in ipsilateral breast tumor recurrence (IBTR), regional recurrence (RR), and contralateral breast cancer (CBC) events among the following 4 subtypes: hormone receptor (HR)+/ERBB2+, HR+/ERBB2−, HR−/ERBB2+, and HR−/ERBB2−. The highest IBTR incidence was in HR−/ERBB2+ tumors, followed by HR−/ERBB2− tumors, peaking at 2 and 9 years after surgery. The highest annual RR was also in HR−/ERBB2− tumors but with a peak at 1 year after surgery, followed by HR−/ERBB2+ and both HR+ subtypes. Annual CBC rates gradually increased for all subtypes, with the HR−/ERBB2− subtype showing the highest rate.